SLSarah Li

Sarah Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Li has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Choroidal Melanoma Treated With Ruthenium‐106 Eye Plaque Brachytherapy: Results of an Australian Statewide Service From November 2020 to January 2025

    by Sarah Li, Lindsay A. McGrath, Timothy Beckman, Adrian Gibbs, Lucy Sim, William Glasson, Sunil Warrier, Andrew Pullar, Luke Nicholls

    Introduction: Uveal melanoma is a rare but aggressive malignancy, predominantly affecting the choroid. This study is the first retrospective review performed on adult choroidal melanoma patients treated with Ruthenium‐106 plaque brachytherapy in Queensland. Method: The study period was November 2020 to January 2025, where patient, tumour, and treatment factors, as well as local control, salvage treatments, radiation retinopathy, and visual acuity were assessed at 6, 12, 24, and 36 months post‐treatment. Results: A total of 151 patients with a mean tumour thickness of 3.85 mm and mean largest basal diameter of 10.2 mm received treatment. A dose of 100 Gy to the tumour apex was prescribed to 88.7% of patients. The short‐term risk factor for disease progression was tumour thickness (odds ratio [OR] 2.01, 95% confidence interval [CI], 1.11–3.87; p = 0.025), whereas tumour to optic nerve distance was a protective factor in both the short‐ (OR 0.55, 95% CI 0.31–0.82; p = 0.013) and long‐term (OR 0.75, 95% CI 0.60–0.90; p = 0.005). At 36 months post‐treatment, local control was 89.5%, the enucleation rate was 3.3%, tumour thickness (OR 1.77, 95% CI 1.1–2.98; p = 0.022) and sclera dose (OR 1.01, 95% CI 1–1.01; p = 0.045) were risk factors for severe radiation retinopathy. Median visual acuity decreased by one Snellen chart line. When tumour distance to optic nerve or foveola is greater than 3 mm, there was minimal change to visual acuity. Conclusion: The findings demonstrate that high‐quality plaque brachytherapy can be delivered effectively at a statewide level.

  • Total Body Irradiation in Australia and New Zealand: A 2024 Practice Survey on Changing Patterns of Care

    by Sarah Li, Nada Hamad, Trieumy Tran Le, Eloise Glassborow, Tom Kupfer, Richard Khor, Angela Viotto, Dane Pope, Kate Ford, Alicia Moggré, et al.

    Introduction: Total body irradiation (TBI) practice varies globally. The optimal technique for TBI has not yet been determined, although guidelines and recommendations are available. Five years after the initial Australia and New Zealand (ANZ) practice survey in 2019, we report updated 2024 TBI practice patterns from 19 ANZ centres who are members of the ANZ Transplant and Cellular Therapies (ANZTCT) TBI Special Interest Group (TBISIG). Method: The 2024 survey was distributed in November 2024. Survey questions covered patient cohorts and caseloads, TBI regimens and dose‐fractionations, TBI techniques, planning considerations, quality assurance, and treatment delivery. For all centres, one staff member from each discipline (Radiation Oncology, Medical Physics, and Radiation Therapy) was invited to respond. Results: Responses were received from all 19 centres. Seven centres use modulated techniques in 2024, whereas only one centre delivered modulated TBI in 2019. Twelve centres use large open fields in 2024, six of which are considering changing to volumetric modulated arc therapy (VMAT) TBI. Compared to large open fields, modulated techniques (1) require dedicated patient immobilisation equipment and treatment planning software, (2) reduce dose to organs at risk (such as lungs and kidneys) below the prescription dose, (3) have higher dose rates, and (4) require more time for planning and treatment delivery. Conclusion: The 2024 survey showed diverse TBI practice patterns in ANZ. Compared to 2019, more centres are using or actively considering the implementation of modulated techniques, such as VMAT TBI, which adds to the complexity of treatment planning and delivery.